{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:30:11Z","timestamp":1770913811841,"version":"3.50.1"},"reference-count":77,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2016,7,2]]},"DOI":"10.1080\/10428194.2016.1185783","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T06:39:52Z","timestamp":1464676792000},"page":"1517-1526","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms"],"prefix":"10.1080","volume":"57","author":[{"given":"Tariq I.","family":"Mughal","sequence":"first","affiliation":[{"name":"Tufts University Medical Center, Boston, MA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Center, Scottsdale, AZ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Levine","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"Hematology, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Orbassano University Hospital, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Papa Giovani XXIII Hospital and Research Center, Bergamo, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,5,31]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.16"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7691"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407792111"},{"key":"e_1_3_2_9_1","article-title":"Dasatinib or Nilotinib discontinuation in chronic phase (CP)-Chronic Myeloid Leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months \u2013 on behalf of the French CML Group Filmc.","volume":"124","author":"Rea D","year":"2014","unstructured":"Rea D, Nicolini FE, Tulliez M, et\u00a0al. Dasatinib or Nilotinib discontinuation in chronic phase (CP)-Chronic Myeloid Leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months \u2013 on behalf of the French CML Group Filmc. Blood. 2014;124: Abstract 811.","journal-title":"Blood"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002030"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000018"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-218842"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.157.157","article-title":"Calr mutants retroviral mouse models lead to a myeloproliferative neoplasm mimicking an essential thrombocythemia progressing to a myelofibrosis.","volume":"124","author":"Marty C","year":"2014","unstructured":"Marty C, Harini N, Pecquet C, et\u00a0al. Calr mutants retroviral mouse models lead to a myeloproliferative neoplasm mimicking an essential thrombocythemia progressing to a myelofibrosis. Blood. 2014;124: Abstract 157.","journal-title":"Blood"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.158.158","article-title":"JAK2V617F and loss of Ezh2 in hematopoietic cells contribute synergistically to myeloproliferative neoplasm initiation potential, and accelerate progression of disease.","volume":"124","author":"Shimizu T","year":"2014","unstructured":"Shimizu T, Hao-Shen H, Kubovcakova L, et\u00a0al. JAK2V617F and loss of Ezh2 in hematopoietic cells contribute synergistically to myeloproliferative neoplasm initiation potential, and accelerate progression of disease. Blood. 2014;124: Abstract 158.","journal-title":"Blood"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567024"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.159.159","article-title":"Loss of EZH2 inhibits erythropoiesis and accelerates the development of myelofibrosis in Jak2V617F knock-in mice.","volume":"124","author":"Yang Y","year":"2014","unstructured":"Yang Y, Akada H, Nath D, et\u00a0al. Loss of EZH2 inhibits erythropoiesis and accelerates the development of myelofibrosis in Jak2V617F knock-in mice. Blood. 2014;124: Abstract 159.","journal-title":"Blood"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.58"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.367"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.04.006"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.822.822","article-title":"The Recql5 helicase is a novel downstream target of Jak2V617F and maintains genome stability in response to replication stress.","volume":"124","author":"Chen E","year":"2014","unstructured":"Chen E, Ahn J-S, Breyfogle LJ, et\u00a0al. The Recql5 helicase is a novel downstream target of Jak2V617F and maintains genome stability in response to replication stress. Blood. 2014;124: Abstract 822.","journal-title":"Blood"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1401873111"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4369"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/blood.V124.21.4528.4528","article-title":"Genetic depletion of Fc gamma receptor 2b affects CML stem cell biology.","volume":"124","author":"Herrmann O","year":"2014","unstructured":"Herrmann O, Wessling CA, Huber M, et\u00a0al. Genetic depletion of Fc gamma receptor 2b affects CML stem cell biology. Blood. 2014;124:4528.","journal-title":"Blood"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125783"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141661"},{"key":"e_1_3_2_26_1","article-title":"Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis.","volume":"124","author":"Kiladjian J-J","year":"2014","unstructured":"Kiladjian J-J, Heidel FH, Vannucchi A, et\u00a0al. Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis. Blood. 2014;124: Abstract 711.","journal-title":"Blood"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1401255"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_2_31_1","article-title":"Primary analysis results from an open-label phase II study of INCB039110, a selective JAK1 inhibitor.","volume":"124","author":"Mascarenhas JO","year":"2014","unstructured":"Mascarenhas JO, Talpaz M, Gupta V, et\u00a0al. Primary analysis results from an open-label phase II study of INCB039110, a selective JAK1 inhibitor. Patients Myelofibrosis Blood. 2014;124: Abstract 714.","journal-title":"Patients Myelofibrosis Blood"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111694"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.713.713","article-title":"Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results.","volume":"124","author":"Verstovsek S","year":"2014","unstructured":"Verstovsek S, Mesa RA, Foltz LM, et\u00a0al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014;124: Abstract 713.","journal-title":"Blood"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0905"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.710.710","article-title":"HARMONY: an open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF).","volume":"124","author":"Durrant S","year":"2014","unstructured":"Durrant S, Koren-Michowitz M, Lavie D, et\u00a0al. HARMONY: an open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF). Blood. 2014;124: Abstract 710.","journal-title":"Blood"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0862"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608984"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0905"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0736"},{"key":"e_1_3_2_41_1","first-page":"1","article-title":"Myeloproliferayive neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.","volume":"1","author":"Koschmeider S","year":"2016","unstructured":"Koschmeider S, Mughal TI, Hasselbalch H, et\u00a0al. Myeloproliferayive neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;1:1\u20137.","journal-title":"Leukemia"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547760"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560441"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.162.162","article-title":"Therapies targeting the MAPK pathway improve bone marrow (BM) fibrosis induced by JAK2V617F.","volume":"124","author":"Shide K","year":"2014","unstructured":"Shide K, Kameda T, Kamiunten A, et\u00a0al. Therapies targeting the MAPK pathway improve bone marrow (BM) fibrosis induced by JAK2V617F. Blood. 2014;124: Abstract 162.","journal-title":"Blood"},{"key":"e_1_3_2_46_1","article-title":"Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).","volume":"33","author":"Mesa RA","year":"2015","unstructured":"Mesa RA, Egyed M, Szoke A, et\u00a0al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2015;33: (Suppl.):Abstract LBA7006.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_47_1","unstructured":"New drug approvals. Pharmacy Therapeut. 2016;41:144\u2013148 153\u2013158 161 194."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.286"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.636.636","article-title":"Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial.","volume":"124","author":"Gotlib JR","year":"2014","unstructured":"Gotlib JR, Kluin-Nelemans HC, George TI, et\u00a0al. Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. Blood. 2014;124: Abstract 636.","journal-title":"Blood"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-678631"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0188-8"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-551929"},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.406.406","article-title":"Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis.","volume":"124","author":"Tefferi A","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Finke C, et\u00a0al. Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis. Blood. 2014;124: Abstract 406.","journal-title":"Blood"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-596676"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.407.407","article-title":"Impact of the molecular profile of malignant clones on the response to interferon alpha (IFNa) therapy in JAK2V617F-negative essential thrombocythemia (ET).","volume":"124","author":"Verger E","year":"2014","unstructured":"Verger E, Cassinat B, Dosquet C, et\u00a0al. Impact of the molecular profile of malignant clones on the response to interferon alpha (IFNa) therapy in JAK2V617F-negative essential thrombocythemia (ET). Blood. 2014;124: Abstract 407.","journal-title":"Blood"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537167"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412098"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32834399a5"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3869"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2041-0"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd.","volume":"124","author":"Larson RA","year":"2014","unstructured":"Larson RA, Kim DW, Issaragrilsil S, et\u00a0al. Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd. Blood. 2014;124: Abstract 4541.","journal-title":"Blood"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056).","volume":"124","author":"Cortes JE","year":"2014","unstructured":"Cortes JE, Saglio G, Baccarani M, et\u00a0al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood. 2014;124: Abstract 152.","journal-title":"Blood"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23938"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_3_2_75_1","article-title":"EPIC: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML).","volume":"124","author":"Lipton J","year":"2015","unstructured":"Lipton J, Chuah C, Guerci-Bresler A, et\u00a0al. EPIC: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood. 2015;124: Abstract 519.","journal-title":"Blood"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"key":"e_1_3_2_77_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.398.398","article-title":"ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia.","volume":"124","author":"Wylie A","year":"2014","unstructured":"Wylie A, Schoepfer J, Berellini G, et\u00a0al. ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood. 2014;124: Abstract 398.","journal-title":"Blood"},{"key":"e_1_3_2_78_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.512.512","article-title":"Cooperative targeting of Bcl-2 family proteins by ABT-199 (GDC-0199) and tyrosine kinase inhibitors to eradicate blast crisis CML and CML stem\/progenitor cells.","volume":"124","author":"Carter BZ","year":"2014","unstructured":"Carter BZ, Mak PY, Mu H, et\u00a0al. Cooperative targeting of Bcl-2 family proteins by ABT-199 (GDC-0199) and tyrosine kinase inhibitors to eradicate blast crisis CML and CML stem\/progenitor cells. Blood. 2014;124: Abstract 512.","journal-title":"Blood"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2016.1185783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:46:28Z","timestamp":1770911188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2016.1185783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,31]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7,2]]}},"alternative-id":["10.1080\/10428194.2016.1185783"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2016.1185783","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}